{
    "eid": "2-s2.0-85121977826",
    "title": "Pharmacological therapeutics: Current trends for metabolic dysfunction-associated fatty liver disease (mafld)",
    "cover-date": "2021-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hepatology",
            "@code": "2721",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Metabolic dysfunction-associated fatty liver disease",
        "Nonalcoholic fatty liver disease",
        "Nonalcoholic steatohepatitis",
        "Pharmacological treatment"
    ],
    "authors": [
        "Thaninee Prasoppokakorn",
        "Panyavee Pitisuttithum",
        "Sombat Treeprasertsuk"
    ],
    "citedby-count": 7,
    "ref-count": 55,
    "ref-list": [
        "A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement",
        "Pathogenesis of nonalcoholic steato-hepatitis: an overview",
        "The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis",
        "Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative",
        "Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis",
        "The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases",
        "Treatment of NAFLD with diet, physical activity and exercise",
        "From NAFLD to MAFLD: implications of a premature change in terminol-ogy",
        "A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD",
        "What\u2019s in a name? renaming \u2018NAFLD\u2019 to \u2018MAFLD\u2019",
        "What\u2019s in a NAme?",
        "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease",
        "The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease",
        "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic stea-tohepatitis",
        "Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis",
        "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis",
        "Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepa-titis",
        "Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis",
        "Meta-analysis: piogl-itazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis",
        "Meta-analysis of randomized controlled trials of pharmaco-logic agents in non-alcoholic steatohepatitis",
        "Nonalcoholic fatty liver disease and recent guideline up-dates",
        "Identification of FDA-approved drugs targeting the Farnesoid X Receptor",
        "Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory re-sponse",
        "Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflamma-tion",
        "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial",
        "Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial",
        "The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model",
        "Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial",
        "Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reduc-tions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results",
        "A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: study design of the TANDEM trial",
        "Peroxisome proliferator-activated receptors and their li-gands: nutritional and clinical implications\u2014a review",
        "The peroxisome prolif-erator-activated receptor: a family of nuclear receptors role in various dis-eases",
        "Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and-delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening",
        "Differential effects of selective-and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages",
        "A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study",
        "New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence",
        "A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis",
        "Saro-glitazar, a PPAR-alpha/gamma agonist, for treatment of nonalcoholic fatty liver disease: a randomized controlled double-blind phase 2 trial",
        "A review of GLP-1 receptor agonists: evolution and advance-ment, through the lens of randomised controlled trials",
        "Lira-glutide safety and efficacy in patients with non-alcoholic steatohepati-tis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study",
        "Liraglutide and cardiovascular outcomes in type 2 diabetes",
        "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis",
        "Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial",
        "MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study",
        "Res-metirom (MGL-3196) for the treatment of non-alcoholic steatohepati-tis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial",
        "Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study",
        "Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA phase 3 study design",
        "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials",
        "Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis",
        "The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis",
        "A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis",
        "Herbal medicine in the treatment of non-alcoholic fatty liver diseases-efficacy, action mecha-nism, and clinical application",
        "The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: a PRISMA-compliant network meta-analysis of randomized controlled trials"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Department of Medicine, Faculty of Medicine, Chulalongkorn University"
    ]
}